LLY

988.57

+2.13%↑

JNJ

225.57

+0.63%↑

ABBV

206.03

-1.03%↓

UNH

363.82

-1.87%↓

AZN

181.33

-1.06%↓

LLY

988.57

+2.13%↑

JNJ

225.57

+0.63%↑

ABBV

206.03

-1.03%↓

UNH

363.82

-1.87%↓

AZN

181.33

-1.06%↓

LLY

988.57

+2.13%↑

JNJ

225.57

+0.63%↑

ABBV

206.03

-1.03%↓

UNH

363.82

-1.87%↓

AZN

181.33

-1.06%↓

LLY

988.57

+2.13%↑

JNJ

225.57

+0.63%↑

ABBV

206.03

-1.03%↓

UNH

363.82

-1.87%↓

AZN

181.33

-1.06%↓

LLY

988.57

+2.13%↑

JNJ

225.57

+0.63%↑

ABBV

206.03

-1.03%↓

UNH

363.82

-1.87%↓

AZN

181.33

-1.06%↓

Search

Beam Therapeutics Inc

Затворен

СекторЗдравеопазване

28.87 -3.77

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

28.48

Максимум

31.23

Ключови измерители

By Trading Economics

Приходи

357M

244M

Продажби

104M

114M

Марж на печалбата

214.091

Служители

511

EBITDA

368M

261M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+60.84% upside

Дивиденти

By Dow Jones

Следващи печалби

11.05.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

122M

3B

Предишно отваряне

32.64

Предишно затваряне

28.87

Настроения в новините

By Acuity

23%

77%

76 / 347 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

Beam Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

5.05.2026 г., 23:43 ч. UTC

Значими събития в новините

New Zealand's Unemployment Rate Falls in 1Q

5.05.2026 г., 23:20 ч. UTC

Горещи акции

Stocks to Watch: AMD, Super Micro, Arista Networks, Freshworks

5.05.2026 г., 21:48 ч. UTC

Печалби

Suncor Energy Reports Higher 1Q Profit on Increased Oil Production

5.05.2026 г., 21:05 ч. UTC

Придобивния, сливания и поглъщания

Canada Antitrust Watchdog Seeks to Kibosh Keyera Deal for Plains' Canada Gas Business -- 4th Update

6.05.2026 г., 00:00 ч. UTC

Пазарно говорене

Canada Energy Minister Signals Energy Investments in the Pipeline -- Market Talk

5.05.2026 г., 23:39 ч. UTC

Пазарно говорене

Gold Rises; Trump Pauses 'Project Freedom' to See if Iran Deal Can Be Finalized -- Market Talk

5.05.2026 г., 22:26 ч. UTC

Пазарно говорене

AMD Data-Center Business Continues to Surge -- Market Talk

5.05.2026 г., 22:20 ч. UTC

Пазарно говорене

AMD's AI Revolution is Still in Early Innings, Analysts Say -- Market Talk

5.05.2026 г., 22:08 ч. UTC

Печалби

Correction to "Palantir Beats Forecasts" on May 4. -- WSJ

5.05.2026 г., 22:07 ч. UTC

Печалби

AMD Stock Soars on Strong Earnings and Growing Confidence About AI -- Barrons.com

5.05.2026 г., 21:48 ч. UTC

Печалби

Pan American Silver 1Q Adj EPS $1.09 >PAAS

5.05.2026 г., 21:48 ч. UTC

Печалби

Pan American Silver 1Q Rev $1.2B >PAAS

5.05.2026 г., 21:42 ч. UTC

Печалби

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5.05.2026 г., 21:38 ч. UTC

Печалби

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5.05.2026 г., 21:30 ч. UTC

Печалби

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5.05.2026 г., 21:29 ч. UTC

Печалби

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5.05.2026 г., 21:26 ч. UTC

Печалби

Strategy Posts Wider Loss as Bitcoin Holdings Hit $64 Billion. The Stock Falls. -- Barrons.com

5.05.2026 г., 21:25 ч. UTC

Печалби

Alcon Inc. 1Q EPS 39c >ALC.EB

5.05.2026 г., 21:25 ч. UTC

Печалби

Alcon Inc. 1Q Rev $2.71B >ALC.EB

5.05.2026 г., 21:24 ч. UTC

Печалби

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5.05.2026 г., 21:18 ч. UTC

Печалби

Mistras Backs 2026 Rev $730M-$750M >MG

5.05.2026 г., 21:17 ч. UTC

Печалби

AMD Stock Jumps on Solid Earnings. AI Continues to Drive Data Center Chips. -- Barrons.com

5.05.2026 г., 21:15 ч. UTC

Печалби

Strategy Records Loss of Nearly $13 Billion as Bitcoin Continues Decline -- WSJ

5.05.2026 г., 21:12 ч. UTC

Печалби

These Stocks Are Today's Movers: Intel, PayPal, Palantir, Shopify, Micron, Duolingo, and More -- Barrons.com

5.05.2026 г., 21:11 ч. UTC

Печалби

SSR Mining 1Q Rev $581.8M >SSRM

5.05.2026 г., 21:10 ч. UTC

Печалби

SSR Mining 1Q Adj EPS $1.15 >SSRM

5.05.2026 г., 21:10 ч. UTC

Печалби

SSR Mining 1Q EPS $1.16 >SSRM

5.05.2026 г., 21:08 ч. UTC

Печалби

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5.05.2026 г., 21:01 ч. UTC

Печалби

Intact Financial 1Q EPS C$4.12 >IFC.T

5.05.2026 г., 21:01 ч. UTC

Горещи акции

Stocks to Watch Recap: Palantir, AMD, Intel, HSBC -- WSJ

Сравнение с други в отрасъла

Ценова промяна

Beam Therapeutics Inc Прогноза

Ценова цел

By TipRanks

60.84% нагоре

12-месечна прогноза

Среден 48.38 USD  60.84%

Висок 80 USD

Нисък 24.18 USD

Според 12 анализатори от Wall Street, предложили 12-месечна ценова цел за Beam Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

12 ratings

11

Купи

1

Задържане

0

Продай

Техническа оценка

By Trading Central

16.225 / 20.17Подкрепа & съпротива

Краткосрочен план

Very Strong Bearish Evidence

Средносрочен план

Very Strong Bearish Evidence

Дългосрочен план

Bearish Evidence

Настроение

By Acuity

76 / 347 Класиране в Здравеопазване

Настроения в новините

Много силни бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Beam Therapeutics Inc

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
help-icon Live chat